Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDInhibikase Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q2 2024 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q3 2024 | 2 | -$0.09 | -$0.08 | -$0.09 |
| Q1 2025 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2025 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q4 2025 | 1 | -$0.15 | -$0.15 | -$0.15 |
| Q1 2026 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2026 | 1 | -$0.21 | -$0.21 | -$0.21 |
Inhibikase Therapeutics, Inc. Earnings Date And Information
Inhibikase Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.65 earnings per share for the quarter, missing analysts' consensus estimates of $-0.38 by $0.27. The company had revenue of 0 for the quarter and had revenue of 260,500 for the year. Inhibikase Therapeutics, Inc. has generated $-4 earnings per share over the last year ($-3.57 diluted earnings per share) and currently has a price-to-earnings ratio of -1.34. Inhibikase Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.
Inhibikase Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.38 | -$0.65 | -0.27 | $0 | $0 |
| 08/14/2024 | Q2 2024 | -$0.58 | -$0.66 | -0.08 | $0 | $0 |
| 05/15/2024 | Q1 2024 | -$0.79 | -$0.73 | 0.06 | $0 | |
| 03/27/2024 | Q4 2023 | -$0.78 | -$0.68 | 0.1 | $1 | |
| 11/14/2023 | Q3 2023 | -$1.12 | -$0.86 | 0.26 | $79,569 | |
| 08/14/2023 | Q2 2023 | -$0.92 | -$1.11 | -0.19 | $116,410 | |
| 05/15/2023 | Q1 2023 | -$0.90 | -$0.87 | 0.03 | $64,521 | |
| 10/16/2023 | Q4 2022 | -$0.99 | $123,440 | |||
| 11/14/2022 | Q3 2022 | -$0.18 | -$1.06 | -0.88 | $200,000 | $0 |
| 08/12/2022 | Q2 2022 | -$0.19 | -$1.10 | -0.91 | $300,000 | $6,552 |
| 05/16/2022 | Q1 2022 | -$0.17 | -$1.10 | -0.93 | $46,031 | |
| 03/31/2022 | Q4 2021 | -$0.17 | -$1.20 | -1.03 | $1,944 | |
| 11/15/2021 | Q3 2021 | -$0.14 | -$1.07 | -0.93 | $200,000 | $328,459 |
| 08/16/2021 | Q2 2021 | -$0.38 | -$1.29 | -0.91 | $300,000 | $1.36 M |
| 05/17/2021 | Q1 2021 | -$1.57 | $1.41 M | |||
| 03/31/2021 | Q4 2020 | -$0.87 | $698,468 | |||
| 09/29/2020 | Q3 2020 | -$0.49 | $37,680 | |||
| 06/29/2020 | Q2 2020 | -$0.31 | $219,585 | |||
| 03/30/2020 | Q1 2020 | -$0.40 | $270,787 | |||
| 12/30/2019 | Q4 2019 | -$0.32 | $240,276 |
Inhibikase Therapeutics, Inc. Earnings: FAQ's
When is Inhibikase Therapeutics, Inc.'s earnings date?
Inhibikase Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.
How can I listen to Inhibikase Therapeutics, Inc.'s earnings conference
call?
The conference call for Inhibikase Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Inhibikase Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Inhibikase Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Inhibikase Therapeutics, Inc. generate each year?
Inhibikase Therapeutics, Inc. (:IKT) has a recorded annual revenue of $260,500.
How much profit does Inhibikase Therapeutics, Inc. generate each year?
Inhibikase Therapeutics, Inc. (:IKT) has a recorded net income of $260,500. Inhibikase Therapeutics, Inc. has generated $-3.57 earnings per share over the last four quarters.
What is Inhibikase Therapeutics, Inc.'s price-to-earnings ratio?
Inhibikase Therapeutics, Inc. (:IKT) has a price-to-earnings ratio of -1.34 and price/earnings-to-growth ratio is -0.19.